Member Info for CTSFO

NickE… I think you’re a bit deluded there. I think it’s best I take your shares off your hands before you lose a lot of money. You can trust me…

🔥🔥🔥🚀🚀🚀🚀!! Just a matter of waiting!!

Thank you, that’s helpful. I was under the impression that breast cancer and AVA6000 was going to be an area specifically trialed / targeted going forward. Potentially very significant if this is the case. Don’t want to wast people’s time explaining this through if it isn’t happening.

Thanks again.

Morning everyone. Happy POETS day. Please excuse my laziness / stupidity/ failed google skills! Does anyone have a link to Dr Tap’s / anyone else’s comments about AVA6000 being trialed in Breast Cancer? Thank in advance. GLA. OROK.

Wyndrum, good morning, I think post removal is algorithm based. If enough complaints are reported, the post is automatically deleted. Might be wrong, but it would make sense. Account deletion is probably only performed by admin’s direct intervention. GLA.

Fingers crossed more people will take an interest now.

I’m wondering when the WTAFNs will start selling.

Https://mcusercontent.com/d9ebd7c1aa0f3dbc5fab42eca/files/94f81303-3e77-d614-8e6b-6cd5bf6b3b9b/AvactaGroupplc_2_10_2024_FINAL_BG.01.pdf

NickE, thank you & very helpful. Rose tinted glasses time for me… firstly you’re absolutely right having Aur Tex IP owned within Structual Heart makes a nice, simple, contained structure to be sold or licensed. I’m wondering how many people are solely employed within it? Would a major want the human research assets as well as the data and research to date? Would they decide on a buy everything and everyone approach to the group? Only a major and RUA BoD know, but it’s a sensible approach? I think it’s going to get very interesting in the next 12 months. I obviously hope much sooner!

Good Luck Always 👏👍

Sorry for the typos.

Not being deliberately argumentative. I’d be surprised if we get an RNS between now and towards the end of the month. Unless it’s a ‘big news has to be immediately RNSd’ type of update. We know the audited accounts and CEO & Chairman’s statements will be issued as part of the accounts. I’m guessing they’ll want to make them as impactful as possible. All positive for the future, lessons learned from the past, this is our plan” type of thing.

GLA

Sort of related:

“ A new treatment for women with a type of advanced breast cancer has been provisionally rejected by the NHS spending watchdog.

In draft guidance the National Institute for Health and Care Excellence (NICE) said it does not recommend elacestrant for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer with an activating ESR1 mutation.

There are currently no targeted treatments available on the NHS for this type of advanced breast cancer that has an ESR1 mutation.

The company proposed that elacestrant (also called Korserdu) is used when the cancer has got worse after at least 12 months of treatment with hormone therapy and a CDK 4/6 inhibitor.

The charity Breast Cancer Now said that elacestrant could bring “precious additional time with loved ones” before disease progression.

But NICE said it is “ready to work with” the manufacturer to address any “uncertainty in evidence” and has requested further clarification and analyses on its effectiveness ahead of their next meeting on 12 November.

The draft guidance is open for public consultation until 22 October.

Helen Knight, director of health technology evaluation at NICE, said: “The main area of uncertainty the committee had to contend with was the estimates for how long elacestrant stopped the disease from getting worse compared with current clinical practice.

“It also meant the committee was unable to confirm at this stage whether a severity modifier could be applied.”

Claire Rowney, chief executive at Breast Cancer Now, said: “We understand that NICE has concerns about uncertainties in the data on the clinical effectiveness of elacestrant, and we urge NICE and Menarini Stemline [the manufacturer] to work closely together to explore all solutions to resolve these issues and see the provisional decision reversed.

“Unless this happens, patients could be denied the precious chance of being offered this targeted treatment option that gives them more time before their cancer progresses.”

It is estimated around 1,000 people would be eligible for treatment with elacestrant if NICE were to recommend it.”

This post is a very useful follow on from the one regarding patents.

Does anyone have experience or an insight into how the SP will be influenced by a major buying the Structual Heart part of the RUA PLC group?

I roughly understand a takeover of the entire group, a major buys our shares at an agreed price, that’s straight forward. How does the market value a cash purchase for a division whilst also accepting the loss of the division as an asset for the group?

Just saying the quality of the posts and posters reflects the quality of the company. Thank you all. 🙏👏🫵🏻💯

Thanks for the update ILS. Good to see the cloaca back on the board. GLA.

Who’s the fluffer?

V1. . . . ROTATE

Hey BV, hope you’re good? As with all these sites, the overwhelming number of adds is a way of forcing people to subscribe. I did to get the immediate sp price information, not sure it’s worth it.

Teaching Everyone To Suck Eggs…

The Audited Accounts come with statements from the Chairman and CEO. I’m hoping the change of release date from end September to end October is to allow for additional good news within these statements. I know significant news has to be RNSd, but nothing stopping the careful timing of events to add impact here. GLA.

666 then sell and put us out of your misery?

An environmentalist of Dr C’s standing doesn’t jet around the world for a jolly. He doesn’t go at Aus without good reason. A bit more than looking at a production line… unless he had to be ‘hands on’ to check it would work for a project / contract that mustn’t fail.

GLA